Compare ABVE & BRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ABVE | BRNS |
|---|---|---|
| Founded | 2019 | 2016 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.3M | 24.1M |
| IPO Year | N/A | 2021 |
| Metric | ABVE | BRNS |
|---|---|---|
| Price | $0.11 | $0.65 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | ★ 6.3M | 17.7K |
| Earning Date | 07-09-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.10 | $0.51 |
| 52 Week High | $6.56 | $2.91 |
| Indicator | ABVE | BRNS |
|---|---|---|
| Relative Strength Index (RSI) | 28.37 | 50.97 |
| Support Level | N/A | $0.65 |
| Resistance Level | $1.07 | $0.75 |
| Average True Range (ATR) | 0.11 | 0.05 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 3.18 | 38.72 |
Above Food Ingredients Inc is a differentiated, regenerative ingredient company. Its products are made with real nutritious, flavorful ingredients and delivered with transparency. Its vision is to create a healthier world one seed, one field, and one bite at a time. With a robust chain of custody of plant proteins, enabled by scaled operations and infrastructure in primary agriculture and processing, and proprietary seed development capabilities that leverage the power of artificial intelligence driven genomics. The company delivers nutritious foods to businesses and consumers with traceability and sustainability. Above Food's consumer products and brands are available in grocers across Canada and the United States.
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.